Phenylalanine 4 Hydroxylase - Pipeline Review, H1 2017 - New Market Report

Boston, MA -- (SBWire) -- 07/13/2017 --According to the recently published report 'Phenylalanine 4 Hydroxylase - Pipeline Review, H1 2017'; Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of the aromatic side-chain of phenylalanine to generate tyrosine. The enzyme works with a molecule called tetrahydrobiopterin (BH4) to carry out this chemical reaction. Tyrosine is used to make several types of hormones, certain chemicals that transmit signals in the brain (neurotransmitters), and a pigment called melanin, which gives hair and skin their color.

The report 'Phenylalanine 4 Hydroxylase - Pipeline Review, H1 2017' outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Get More Details on this Report and a Full Table of Contents at Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H1 2017

It also reviewsalso reviews key players involved in Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 4 and 1 respectively. Report covers products from therapy areas Metabolic Disorders which include indications Phenylketonuria (PKU).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The report provides a snapshot of the global therapeutic landscape for Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1)

-The report reviews Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics and enlists all their major and minor projects

-The report assesses Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics

Reasons to Get this Report

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1)

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned in this Report: Codexis Inc, Dimension Therapeutics Inc, Synthetic Biologics Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2017
-Steroid 17-Alpha-Hydroxylase/17,20 Lyase (17-Alpha-Hydroxyprogesterone Aldolase or CYPXVII or Cytochrome P450 17A1 or Cytochrome P450-C17 or Cytochrome P450c17 or Steroid 17-Alpha-Monooxygenase or CYP17A1 or CYP17 or EC 1.14.99.9 or EC 4.1.2.30) - Pipelin
-Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H1 2017
-Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017
-Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform - Pipeline Review, H1 2017